61 phenotypes from 6 alleles in 9 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Etv6em1(IMPC)Rbrc/Etv6+ C57BL/6NJcl-Etv6em1(IMPC)Rbrc/Rbrc	abnormal heart morphology	J:211773
	abnormal heart shape	J:211773
	abnormal heart weight	J:211773
	abnormal liver morphology	J:211773
	decreased bone mineral density	J:211773
	decreased circulating calcium level	J:211773
	decreased circulating cholesterol level	J:211773
	decreased circulating HDL cholesterol level	J:211773
	decreased circulating serum albumin level	J:211773
	decreased circulating total protein level	J:211773
	decreased erythrocyte cell number	J:211773
	enlarged heart	J:211773
	increased blood uric acid level	J:211773
	increased heart atrium size	J:211773
	increased kidney weight	J:211773
	increased large unstained cell number	J:211773
	increased spleen weight	J:211773
	small liver	J:211773
	thrombocytopenia	J:211773
Etv6em1(IMPC)Rbrc/Etv6em1(IMPC)Rbrc C57BL/6NJcl-Etv6em1(IMPC)Rbrc/Rbrc	preweaning lethality, complete penetrance	J:211773
Etv6em3Knic/Etv6+ involves: C57BL/6J	abnormal B cell number	J:342774
	abnormal common myeloid progenitor cell morphology	J:342774
	abnormal hematopoietic precursor cell morphology	J:342774
	abnormal hemopoiesis	J:342774
	abnormal platelet shape	J:342774
	normal hematopoietic system phenotype	J:342774
	impaired blood coagulation	J:342774
Etv6tm1(RUNX1)Haho/Etv6+ Tg(Mx1-cre)1Cgn/0 involves: 129S1/Sv * C57BL/6 * CBA	abnormal bone marrow cell physiology	J:151639
	abnormal common lymphocyte progenitor cell morphology	J:151639
	abnormal common myeloid progenitor cell morphology	J:151639
	abnormal definitive hematopoiesis	J:151639
	abnormal lymphopoiesis	J:151639
	decreased B cell number	J:151639
	decreased erythroid progenitor cell number	J:151639
	decreased lymphocyte cell number	J:151639
	decreased neutrophil cell number	J:151639
	normal immune system phenotype	J:151639
	increased hematopoietic stem cell number	J:151639
	increased incidence of tumors by chemical induction	J:151639
	increased leukemia incidence	J:151639
	myeloid hyperplasia	J:151639
	thrombocytopenia	J:151639
Etv6tm1(RUNX1)Haho/Etv6+ Tg(Gata1-cre)1Sho/0 involves: 129S1/Sv * C57BL/6 * CD-1 * Swiss Webster	abnormal B cell differentiation	J:151639
	normal embryo phenotype	J:151639
	embryonic lethality during organogenesis, incomplete penetrance	J:151639
	normal immune system phenotype	J:151639
	intestinal edema	J:151639
	normal neoplasm	J:151639
	postnatal growth retardation	J:151639
	postnatal lethality	J:151639
Etv6tm1(RUNX1)Haho/Etv6+ Tg(CD2-icre)4Kio/0 involves: 129S1/Sv * C57BL/6 * C57BL/10 * CBA/Ca	normal immune system phenotype	J:151639
Etv6tm1(RUNX1)Haho/Etv6+ Tg(VAV1-cre)1Graf/0 involves: 129S1/Sv * C57BL/6	abnormal myeloblast morphology/development	J:151639
	arrested B cell differentiation	J:151639
	decreased B cell number	J:151639
	decreased pre-B cell number	J:151639
	decreased pro-B cell number	J:151639
	increased hematopoietic stem cell number	J:151639
Etv6tm1(RUNX1)Haho/Etv6tm1(RUNX1)Haho B6.129S1-Etv6tm1(Runx1)Haho	prenatal lethality, complete penetrance	J:151639
Etv6tm1Sho/Etv6tm1Sho involves: 129S4/SvJae * C57BL/6	abnormal visceral yolk sac morphology	J:42409
	absent vitelline blood vessels	J:42409
	normal cardiovascular system phenotype	J:42409
	normal embryo phenotype	J:42409
	embryonic growth retardation	J:42409
	embryonic lethality during organogenesis, complete penetrance	J:42409
	enlarged pericardium	J:42409
Etv6tm2.1Sho/Etv6tm2.1Sho involves: 129S1/Sv	abnormal erythropoiesis	J:93052
	absent vitelline blood vessels	J:93052
	embryonic lethality during organogenesis, incomplete penetrance	J:93052
	prenatal lethality, complete penetrance	J:93052
Etv6tm2Sho/Etv6tm2Sho involves: 129S1/Sv	no abnormal phenotype detected	J:93052
Etv6tm2Sho/Etv6tm2Sho Tg(Gata1-cre)1Sho/? involves: 129S1/Sv	abnormal megakaryocyte differentiation	J:93052
	thrombocytopenia	J:93052
Etv6tm2Sho/Etv6tm2Sho Tg(Mx1-cre)1Cgn/? involves: 129S1/Sv * C57BL/6 * CBA	decreased neutrophil cell number	J:93052
	thrombocytopenia	J:93052